CD200 and B-cell chronic lymphocytic leukemia: CD200 is also emerging as a potential therapeutic target in CLL [15,16,17], and promising results have been recently obtained by a first-in-human study investigating samalizumab, a recombinant humanized monoclonal anti-CD200 antibody, suggesting that CD200 could represent a novel target for immune checkpoint inhibitor drugs [18].